AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.79
-1.78 (-3.66%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close48.57
Open48.75
Bid0.00 x 800
Ask0.00 x 1300
Day's Range45.39 - 49.97
52 Week Range1.94 - 50.00
Volume1277222
Avg. Volume1,101,349
Market Cap1.6B
Beta (5Y Monthly)2.87
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateMar 12, 2020 - Mar 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.57
  • Did Hedge Funds Drop The Ball On Axsome Therapeutics, Inc. (AXSM)?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Axsome Therapeutics, Inc. (AXSM)?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Benzinga

    12 Biotech Stocks Primed For A Short Squeeze

    Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...

  • Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
    Zacks

    Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

  • Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up
    Zacks

    Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

    Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Implied Volatility Surging for Axsome (AXSM) Stock Options
    Zacks

    Implied Volatility Surging for Axsome (AXSM) Stock Options

    Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

  • GlobeNewswire

    Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

    NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase 2 trial. AXS-12 also significantly reduced excessive daytime sleepiness (EDS), and improved cognitive function, sleep quality and sleep-related symptoms.

  • Top Small Cap Stocks for December 2019
    Investopedia

    Top Small Cap Stocks for December 2019

    Small cap stocks are listed companies that have market capitalizations ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Owing to their small-sized classification, companies in industrial sectors make up a large share of the small cap universe.

  • GlobeNewswire

    Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting an R&D conference call and webcast with slides on Monday, November 25, 2019 at 9:00 AM Eastern Time with key opinion leaders (KOLs) focusing on AXS-07 (MoSEIC™ meloxicam/rizatriptan) and the unmet needs in the acute treatment of migraine. AXS-07 is being evaluated in the ongoing MOMENTUM Phase 3 trial in migraine patients with a history of inadequate response to prior acute treatments, with topline results expected in the fourth quarter of 2019. The investor call will feature presentations from Dr. Stewart J. Tepper, Professor of Neurology at The Geisel School of Medicine at Dartmouth; and Dr. Richard B. Lipton, Professor and Vice Chair of Neurology, and Director of the Montefiore Headache Center, at the Albert Einstein College of Medicine.

  • Thomson Reuters StreetEvents

    Edited Transcript of AXSM earnings conference call or presentation 7-Nov-19 1:00pm GMT

    Q3 2019 Axsome Therapeutics Inc Earnings Call

  • GlobeNewswire

    Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2019. “So far this year, we have significantly advanced our pipeline of differentiated investigational medicines that have the potential to transform the lives of many of the millions of people living with difficult-to-treat CNS disorders.

  • GlobeNewswire

    Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2019 on Thursday, November 7, 2019 before the opening of the U.S. financial markets.

  • Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)

    Is Axsome Therapeutics, Inc. (NASDAQ:AXSM) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]

  • GlobeNewswire

    Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced results of the “Migraine Treatment Needs and Physician Receptivity” (MINDSET) survey, which demonstrated a significant unmet need for more efficacious acute migraine treatments and a high willingness of physicians to prescribe AXS-07 should it meet the objectives of the ongoing MOMENTUM Phase 3 trial in patients with difficult-to-treat migraines. MINDSET surveyed 106 neurologists and other migraine-treating physicians, who collectively treat more than 50,000 migraine patients annually, to understand physicians’ views of the unmet needs in the acute treatment of migraine and their potential receptivity to AXS-07.

  • GlobeNewswire

    Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announces the initiation of the INTERCEPT trial, a Phase 3 study evaluating the early treatment of migraine with AXS-07 (MoSEIC™ meloxicam/rizatriptan), the Company’s novel, oral, investigational medicine with distinct dual mechanisms of action for the acute treatment of migraine. The Company separately announced results of the MINDSET survey of physicians who treat in aggregate more than 50,000 migraine patients annually.

  • GlobeNewswire

    Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the CONCERT study, a Phase 2, randomized, double-blind, placebo-controlled, crossover, trial of AXS-12 in patients with narcolepsy. AXS-12 (reboxetine) is a novel, oral, potent and highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy.

  • GlobeNewswire

    Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient enrollment in the GEMINI study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in patients with major depressive disorder (MDD). AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. Axsome remains on track to report topline results from GEMINI in the fourth quarter of 2019.

  • Riding 2 Big Winners in Small Biotech
    TheStreet.com

    Riding 2 Big Winners in Small Biotech

    Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.

  • Axsome (AXSM) Catches Eye: Stock Jumps 9.3%
    Zacks

    Axsome (AXSM) Catches Eye: Stock Jumps 9.3%

    Axsome (AXSM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • GlobeNewswire

    Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference

    GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD on track for readout of topline results in 4Q 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for readout of.

  • Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
    Zacks

    Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?

    Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

  • CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM)
    Simply Wall St.

    CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM)

    Even if it's not a huge purchase, we think it was good to see that Nick Pizzie, the CFO & Principal Accounting Officer...

  • Benzinga

    Axsome Shares Flirt With Record High: How Much Upside Is Left?

    Axsome Therapeutics Inc (NASDAQ: AXSM ) by far has been the hottest biotech of the year, clocking in gains of about 1,000% in 2019. Its market capitalization has swelled to close to $1 billion thanks to ...

  • How Much Are Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Spending On Buying Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • GlobeNewswire

    Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019. A live webcast and archive of the event can be viewed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at www.axsome.com. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options.